Featured 13F manager
DME Capital Management David Einhorn
New York, NY 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $3.9B
- 46 holds
- 2026 Q2
- +22.5% QoQ
- Top 5 38.2%
David Einhorn files DME Capital Management as a Form 13F. The latest book is 2026 Q2 at $3.9B, up 22.5% QoQ, led by Green Brick Partners, Fluor, and Core Natural Resources.
Portfolio
top 5 38.2% · top 10 52.8%
- GRBK - Green Brick Partners 19.4%
- FLR - Fluor 6.2%
- CNR - Core Natural Resources 4.7%
- BHF - Brighthouse Finl 4.6%
- ACHC — 3.3%
- PENN - Penn Entertainment 3.2%
- FBIN - Fortune Brands 3.1%
- PCG - Pg And E 2.9%
- CNC - Centene Del 2.7%
- PKG - Graphic Packaging 2.7%
- SNX - Td Synnex 2.6%
- TEVA - Teva Pharmaceutical Inds 2.5%
- Other 42.1%
AUM over time
Book
| GRBK - Green Brick Partners | Hold | 17,418,668 | $20.52 | $357M | |
| BHF - Brighthouse Finl | Hold | 3,920,000 | $45.23 | $177M | |
| Holding | Hold | 1,514,855 | $81.68 | $124M | |
| TECK - Teck Resources · CL B | Hold | 4,527,864 | $24.91 | $113M | |
| Change Healthcare | Hold | 3,586,805 | $20.94 | $75M | |
| CC - Chemours | Hold | 2,322,419 | $29.06 | $67M | |
| CEIXEUR - Consol Energy | Hold | 2,119,029 | $26.02 | $55M | |
| CNXC - Concentrix | Hold | 266,009 | $177.00 | $47M | |
| ODP1 - The Odp | Hold | 1,146,932 | $40.16 | $46M | |
| Danimer Scientific · CL A | Hold | 2,358,172 | $16.34 | $39M | |
| GPRO - Gopro · CL A | Hold | 3,664,900 | $9.36 | $34M | |
| REZI - Resideo Technologies | Hold | 1,365,063 | $24.79 | $34M | |
| SLV - Ishares Silver Tr | Hold | 1,558,000 | $20.52 | $32M | |
| AER - Aercap | Hold | 528,858 | $57.81 | $31M | |
| Hold | 487,500 | $60.39 | $29M | ||
| CPRI - Capri | Hold | 606,000 | $48.41 | $29M | |
| SATS - Echostar · CL A | Hold | 1,027,153 | $25.51 | $26M | |
| GLD - Spdr Gold Tr | Hold | 115,880 | $164.22 | $19M | |
| PKG - Graphic Packaging | Hold | 832,270 | $19.04 | $16M | |
| Jack In The Box | Hold | 148,800 | $97.33 | $14M | |
| LIVN - Livanova | Hold | 177,500 | $79.19 | $14M | |
| SONO - Sonos | Hold | 363,680 | $32.36 | $12M | |
| Neubase Therapeutics | Hold | 2,727,027 | $3.61 | $10M | |
| PLBY Group | Hold | 410,000 | $23.57 | $10M | |
| GPOR - Gulfport Energy | Hold | 106,054 | $82.20 | $9M | |
| NWSA - NEWS · CL B | Hold | 361,291 | $23.23 | $8M | |
| Fubotv | Hold | 322,580 | $23.96 | $8M | |
| Freyr Battery | Hold | 700,000 | $9.87 | $7M | |
| ASTS - Ast Spacemobile · CL A | Hold | 570,000 | $10.82 | $6M | |
| Extraction Oil & Gas | Hold | 99,485 | $56.45 | $6M | |
| Playstudios · CLASS A | Hold | 979,800 | $4.56 | $4M | |
| GANX - Gain Therapeutics | Hold | 546,560 | $7.44 | $4M | |
| Holding | Hold | 373,104 | $10.10 | $4M | |
| VSXY - Victorias Secret And | Hold | 64,728 | $55.26 | $4M | |
| Waverley Capital Acquis | Hold | 350,000 | $9.86 | $3M | |
| EXPE - Expedia Group | Hold | 20,000 | $163.90 | $3M | |
| Finserv Acquisition Ii | Hold | 315,000 | $9.86 | $3M | |
| CNX - Cnx Res | Hold | 222,715 | $12.62 | $3M | |
| Panacea Acquisition Ii · CL A | Hold | 275,000 | $9.77 | $3M | |
| Stryve Foods · CLASS A | Hold | 150,000 | $5.35 | $803K | |
| Altimeter Growth 2 · CL A | Hold | 56,908 | $9.89 | $563K | |
| NUVB - Nuvation Bio · CL A | Hold | 34,995 | $9.94 | $348K | |
| Adamis Pharmaceuticals | Hold | 292,366 | $0.9680 | $283K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 46 | $3.9B | +22.5% | 13F-HR | 8/14/2026 | 000117266126003786 |
| 2026 Q1 | 45 | $3.2B | +12.0% | 13F-HR | 5/15/2026 | 000117266126002341 |
| 2025 Q4 | 41 | $2.8B | +12.1% | 13F-HR | 2/17/2026 | 000117266126001122 |
| 2025 Q3 | 37 | $2.5B | +9.3% | 13F-HR | 11/14/2025 | 000117266125005032 |
| 2025 Q2 | 34 | $2.3B | +17.8% | 13F-HR | 8/14/2025 | 000117266125003351 |
| 2025 Q1 | 33 | $2B | +1.5% | 13F-HR | 5/15/2025 | 000117266125002307 |
| 2024 Q4 | 36 | $1.9B | −19.1% | 13F-HR | 2/14/2025 | 000117266125001165 |
| 2024 Q3 | 38 | $2.4B | +17.6% | 13F-HR | 11/14/2024 | 000117266124005240 |
| 2024 Q2 | 39 | $2B | −6.5% | 13F-HR | 8/14/2024 | 000117266124003549 |
| 2024 Q1 | 42 | $2.2B | — | 13F-HR | 5/15/2024 | 000117266124002489 |
| 2023 Q4 | 40 | $2B | +16.3% | 13F-HR | 2/14/2024 | 000117266124001512 |
| 2023 Q3 | 39 | $1.8B | −17.4% | 13F-HR | 11/14/2023 | 000117266123004012 |
| 2023 Q2 | 41 | $2.1B | +15.9% | 13F-HR | 8/14/2023 | 000117266123003174 |
| 2023 Q1 | 39 | $1.8B | +27.4% | 13F-HR | 5/15/2023 | 000117266123002282 |
| 2022 Q4 | 42 | $1.4B | +2.3% | 13F-HR | 2/14/2023 | 000117266123001336 |
| 2022 Q3 | 42 | $1.4B | +9.8% | 13F-HR | 11/14/2022 | 000117266122002565 |
| 2022 Q2 | 47 | $1.3B | −18.3% | 13F-HR | 8/15/2022 | 000117266122002019 |
| 2022 Q1 | 52 | $1.6B | −10.0% | 13F-HR | 5/16/2022 | 000117266122001474 |
| 2021 Q4 | 57 | $1.7B | +17.2% | 13F-HR | 2/14/2022 | 000117266122000884 |
| 2021 Q3 | 58 | $1.5B | — | 13F-HR | 11/15/2021 | 000117266121002370 |
About
DME Capital Management
20 processed 13Fs on this site · 2021 Q3–2026 Q2